NCCN 指南洞察版：B 细胞淋巴瘤，第 6 版. 2023 年。

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

机构信息

Memorial Sloan Kettering Cancer Center.

Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

出版信息

J Natl Compr Canc Netw. 2023 Nov;21(11):1118-1131. doi: 10.6004/jnccn.2023.0057.

DOI:10.6004/jnccn.2023.0057

PMID:37935098

Abstract

Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

摘要

新型靶向治疗（小分子抑制剂、抗体药物偶联物和 CD19 导向疗法）改变了复发/难治性 B 细胞淋巴瘤的治疗格局。布鲁顿酪氨酸激酶（BTK）抑制剂在复发/难治性和一线治疗中继续发展，用于治疗套细胞淋巴瘤（MCL）。抗 CD19 CAR T 细胞疗法现已成为复发/难治性滤泡性淋巴瘤（FL）、弥漫性大 B 细胞淋巴瘤（DLBCL）和 MCL 的有效且获批的治疗选择。双特异性 T 细胞衔接器是一种新的免疫治疗方法，适用于多种治疗方案后复发的 FL 和 DLBCL，包括之前的 CAR T 细胞治疗。这些 NCCN 指南洞察强调了 NCCN 指南对 FL、DLBCL 和 MCL 治疗的重大更新。